Axplora Announces €6.5 Million Investment at Vizag Site
Axplora announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience.
This announcement follows the successful completion of routine USFDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of the company’s PharmaZell Business Unit. Combined, these milestones underscore Axplora’s long-term commitment to India as a strategic pillar of its global operations and its dedication to maintaining world-class quality and compliance standards.
The expansion project at Vizag will increase output and create new employment opportunities, enhancing Axplora’s ability to meet growing global demand for high-value pharmaceutical ingredients. The investment also advances the company’s sustainability goals by supporting efficient, vertically integrated production at a single site.
“This investment reflects Axplora’s strategic commitment to operational excellence and customer-centric growth,” said Martin Meeson, CEO of Axplora. “By strengthening our infrastructure in Vizag, we are enhancing our ability to deliver high-quality, reliable, and scalable solutions to customers worldwide.”
Both the Vizag and Chennai sites successfully completed routine inspections by the US Food and Drug Administration (USFDA) in 2025, each concluding with a Voluntary Action Indicated (VAI) classification. These outcomes affirm the company’s robust compliance with international regulatory standards and its proactive approach to continuous improvement.
The inspector at the Chennai facility highlighted several areas of excellence, including the strong and consistent implementation of current Good Manufacturing Practices (cGMP), streamlined and efficient document management and retrieval processes, and the high standards maintained in facility upkeep and overall site hygiene.
